Baricitinib
Skin Diseases
Eli Lilly and CompanySmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Skin Diseases cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Mometasone North Central Cancer Treatment Group | Phase 3 | BB |
Docetaxel Binghe Xu | Phase 3 | B |
Capecitabine Binghe Xu | Phase 3 | B |
Lmb-2 National Cancer Institute (NCI) | Phase 2 | B |
Trabectedin Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 2 | B |
View all 14 →
Same molecule, other indications
Baricitinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →